Sangamo Therapeutics, Inc.
SGMO
$0.6223
-$0.0846-11.97%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -97.94M | -134.84M | -249.68M | -328.05M | -257.83M |
| Total Depreciation and Amortization | 9.36M | 10.24M | 15.53M | 19.14M | 22.19M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.93M | 20.33M | 69.02M | 115.83M | 174.83M |
| Change in Net Operating Assets | 4.51M | -10.05M | -8.25M | -14.12M | -164.03M |
| Cash from Operations | -67.14M | -114.33M | -173.38M | -207.21M | -224.84M |
| Capital Expenditure | -267.00K | -2.79M | -5.42M | -10.96M | -21.16M |
| Sale of Property, Plant, and Equipment | 1.95M | 475.00K | 127.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 35.84M | 76.22M | 116.59M | 164.60M | 174.69M |
| Cash from Investing | 37.52M | 73.91M | 111.30M | 153.64M | 153.53M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 29.74M | 22.74M | 22.74M | 29.45M | 16.04M |
| Repurchase of Common Stock | -1.36M | -1.19M | -1.09M | -746.00K | -1.45M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 28.38M | 21.55M | 21.66M | 28.71M | 14.59M |
| Foreign Exchange rate Adjustments | -2.05M | 1.55M | -124.00K | 446.00K | 1.48M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.29M | -17.31M | -40.54M | -24.41M | -55.24M |
